![]()
|
|
||||||||
J Biol Chem, Vol. 274, Issue 41, 29063-29070, October 8, 1999
From the IGH-CNRS UPR 1142, 141 rue de la Cardonille,
34396 Montpellier cedex 05, France and the The molecular mechanisms underlying the
developmental regulation of L-type voltage-dependent
Ca2+ channels (VDCCs) are still unknown. In this
study, we have characterized the expression patterns of skeletal
( It is accepted that adult cardiac myocytes exhibit tissue-specific
expression of L-type voltage-dependent calcium channels (VDCCs),1 i.e. the
class C ( The skeletal muscle, in which myoblasts fuse to form mature
multinucleated myotubes, is a good model to address basic mechanisms involved in muscle differentiation (6). It is now clear that the
expression of the skeletal L-type VDCC subtype specifically correlates
with skeletal muscle differentiation (7). In the cardiac muscle
lineage, cell proliferation and differentiation are not mutually
exclusive events, and embryonic cardiac myocytes undergo maturation
during development. The appearance of L-type VDCCs occurs at early
stages of cardiogenesis (8, 9). However, the study of L-type VDCC
expression during cardiogenic differentiation is a difficult task,
mainly because of the laboriousness of obtaining embryonic cardiac
cells from early embryos.
The development of in vitro models that recapitulate
molecular events underlying the establishment of the cardiac muscle
phenotype is an important step toward understanding the mechanisms
involved in the regulation of cardiac ion channel gene expression (9). An interesting experimental model is the clonal cardiac cell line H9C2
derived from embryonic rat heart (10). This cell line has been studied
for its electrophysiological properties, and it was demonstrated that
H9C2 cells exhibit L-type VDCCs with cardiac-specific characteristics
(11), although concomitant expression of skeletal L-type VDCCs occurs
in H9C2 cells (12).
Here, we present evidence that the H9C2 cell line is valuable for the
investigation of the ontogenic properties of these two Ca2+
channel isotypes. We have conducted experiments to characterize the
changes in the expression of VDCCs during differentiation of H9C2
cells. We show that upon a chronic treatment with 10 nM all-trans-retinoic acid (all-trans-RA), H9C2
cells exhibit enhanced cardiac Ca2+ channel expression as a
consequence of the maintenance of their cardiac phenotype. By contrast,
myogenic transdifferentiation is inhibited. The data unambiguously
demonstrate that the functional expression of muscle L type VDCC
isotypes ( Cell Culture--
H9C2 cells obtained from the European
Collection of Cell Cultures were grown as a stock of cells in culture
flasks in Dulbecco's modified Eagle's medium supplemented with 10%
fetal calf serum (FCS) (Eurobio), glutamine (2 mM),
penicillin (100 IU/ml), and streptomycin (100 µg/ml) under standard
culture conditions (37 °C, 5% CO2, and water-saturated
atmosphere). Before confluence, cells were split, plated at a lower
density in Petri dishes in 10% FCS culture medium and cultured for 1 day. Cells were then cultured in Dulbecco's modified Eagle's medium
supplemented with 1% FCS. The culture medium was replaced every 2 days. Stimulation with retinoic acid analogs was performed daily.
All-trans-RA, as well as 9-cis-RA (Sigma) were
diluted in the dark in Me2SO (1 mM stock
solution) and stored at Electrophysiology--
Calcium channel currents were recorded by
means of the whole cell configuration of the patch clamp technique
using an Axopatch 200A amplifier (Axon Instruments, CA) and
Ba2+ (40 mM) as the charge carrier. The bath
solution was 40 mM Ba(OH)2, 80 mM
N-methyl-D-glutamine, 40 mM
glutamate, 10 mM Hepes, 2 mM MgCl2,
pH 7.4, with CH3SO3H. The intracellular
solution was 140 mM
N-methyl-D-glutamine, 20 mM EGTA, 15 mM Hepes, 2 mM MgCl2, pH 7.4, with
CH3SO3H. Electrophysiological recordings were
performed as described elsewhere (13).
RT-PCR Experiments--
Multiplex RT-PCR detection of
transcripts encoding
PCR primers that were designed according to Mejia-Alvarez et
al. (12) to amplify transcripts encoding Characteristics of the Primary Antibodies--
A monoclonal
antibody developed by Morton and Froehner (16) that recognizes an
extracellular epitope of the Western Blotting and Immunoblotting Analyses--
Membrane
extracts were prepared from 2-month-old Wistar rats. Heart and skeletal
muscles were quickly removed after death. Tissues were disrupted at
room temperature in the extraction buffer prepared extemporaneously (50 mM Tris-HCl, pH 8, 0.1% saponin; 1 mM
phenylmethylsulfonyl fluoride, 0.1 mg/ml leupeptin, 0.1 mg/ml soybean
trypsin inhibitor) using a polytron homogenizer. Homogenates were
centrifuged for 5 min at 3500 × g, and supernatants
were collected and boiled for 5 min in a denaturing solution containing Indirect Immunofluorescence Experiments--
Cells were rinsed
with PBS, fixed overnight at 4 °C in a paraformaldehyde solution
(4% in PBS), and then washed three times for 5 min each with PBS.
Blocking of nonspecific sites was performed by incubating cells in a
PBS-bovine serum albumin (3%) solution for 30 min at 37 °C. When
required, cell permeabilization was performed by treating with 0.03%
Triton in PBS for 5-10 min. Cells were then incubated for either
1 h at 37 °C or overnight at 4 °C with the first antibody at
the desired dilution in PBS-bovine serum albumin. Cells were washed
three times with PBS and incubated for 45 min at 37 °C with goat
anti-rabbit or goat anti-mouse secondary antibodies, fluorescein
isothiocyanate-conjugated (Cappel). They were then washed three times
with PBS buffer and distilled water before labeling nuclei by a 1-min
treatment with Hoescht 33258 dye (Sigma). Coverslips were
washed in distilled water and mounted in a mixture containing 15%
(w/v) Airvol 205, 33% glycerol dissolved in Tris-HCl buffer. Digital
images acquired on a microscope (Leica) using a Kodak DCS420 camera
were analyzed with no or a minimal image treatment on a Silicon
Graphics workstation with the Imgwork and Iris Showcase 3.2 software
packages (Silicon Graphics) or Adobe Photoshop (version 4.0). Data were
printed using a Kodak Colorease thermal sublimation printer.
L-type Ca2+ Currents in H9C2 Myoblasts
ICARD--
Using the patch clamp method, we have
investigated the Ca2+ channel properties in H9C2 cells
using 40 mM Ba2+ as the charge carrier. Freshly
plated cells (Fig. 1A)
proliferated rapidly and exhibited an L-type Ba2+ current
(Fig. 1B), as described for cardiac myocytes (2). The
density of this current, named ICARD, was 3.2 ± 0.7 pA/pF, n = 31 (Fig. 1C). ICARD
was detected in all mononucleated cells, whatever their morphology.
This current was sensitive to both dihydropyridine antagonists and
agonist and was up-regulated by the ISKM--
When H9C2 cells reached confluence, they
were switched to a 1% FCS medium, and several elongated and
multinucleated cells were observed (Fig. 1, D and
G). These cells exhibited a specific labeling for myogenin
as well as for troponin T and MyoD (18) and thus could be identified as
skeletal muscle myotubes. H9C2 myotubes displayed a very slow
activating and inactivating L-type Ba2+ current (Fig. 1,
E and H). This current, named ISKM,
resembled the one recorded in skeletal muscle myotubes and in a variety of differentiated skeletal muscle cell lines and primary cultures (19).
The distinct kinetics of ISKM and ICARD allowed
us to easily identify cells that exhibit the two Ba2+
current subtypes (Fig. 1E), as well as to measure their
respective amplitudes. Indeed, we found that in small myotubes (2-5
nuclei, n = 12), ICARD (2.5 ± 0.8 pA/pF) was generally associated with ISKM (3.1 ± 0.7 pA/pF) (Fig. 1, E and F). These two currents, despite their difference in activation kinetics, were clearly high
voltage activated and dihydropyridine-sensitive. In addition, we never
identified low voltage activated T-type Ba2+ current in
such myotubes (n = 50). In larger myotubes with up to 5 nuclei (Fig. 1G), ISKM was of higher density
(ISKM, 8 ± 2.3 pA/pF; n = 6), and no
more ICARD was detected (Fig. 1, H and
I). These data indicate that the functional expression of
skeletal muscle L-type Ca2+ channels occurs concomitantly
with the fusion of the myoblasts. Our electrophysiological experiments,
conducted on a large number of cells (up to 150) have revealed that the
presence of ISKM is exclusive of myotubes. However, it is
important to note that ICARD was still detected in
mononucleated cells present in confluent cultures, with an average
Ba2+ current density of 1.8 ± 1.1 pA/pF
(n = 25).
Enhanced Cardiac Differentiation in RA-treated H9C2 Cells
The H9C2 cell line was derived from rat cardiac ventricule
embryonic cardiocytes (10). Freshly plated cells were strictly mononucleated myoblasts, as judged from DNA staining by Hoescht reagent. We took advantage of this cellular model, capable of expressing multiple isoforms of the L-type Ca2+ channels,
to seek factors that would modulate muscle differentiation together
with Ca2+ channel expression. We describe here the effects
of a chronic exposure of differentiating H9C2 cells to RA (Fig.
2). Treatment of H9C2 cells with RA
analogs (10 nM all-trans- or 9-cis-)
for 5-7 days markedly reduced proliferation, as judged from the lower percentage of BrdUrd-labeled nuclei after short exposure (30 min) of
the cells to this reagent (not shown). RA-treated cells exhibited morphological changes with rather large and rounded cells (Fig. 2A), distinct from the elongated myotubes present in control
cultures (Fig. 2B) or in Me2SO- or cAMP-treated
cultures (not shown). Large cells found in both RA-exposed cultures
(Fig. 2C) and the myotubes (Fig. 2D) were
multinucleated. These various parameters define the morphological
phenotype of RA-exposed H9C2 cells, which requires a low FCS
concentration (1%).
Biochemical differentiation of H9C2 cells was characterized using
skeletal and cardiac protein markers. RA treatment of differentiating H9C2 cells markedly altered myogenic differentiation because none of
the multinucleated cells were positive for the expression of myogenin
(Fig. 2E) and troponin T (Fig. 2G). By contrast,
myotubes present in control differentiated cultures (control, 1% FCS,
1% Me2SO, and 1 µM 8-Br cAMP) showed typical
staining for myogenin (Fig. 2F), MyoD, and troponin T (Fig.
2H). After 4-5 days of culture in 1% FCS, 30-40% of
troponin T-positive cells could be observed. Differentiating H9C2 cells
were then checked for the presence of the ventricular MLC-2v, a well
characterized marker of cardiac differentiation (20, 21). Fig.
2I shows that H9C2 cells treated with RA exhibited an
intense staining for MLC-2v, typical of that obtained with cultured
cardiac cells. By contrast, H9C2 cells cultivated in myogenic
differentiation conditions displayed only a faint staining for MLC-2v
(Fig. 2J). At the myoblast stage, H9C2 cells were positive
for both MLCv-2a and MLC-2v cardiac markers (not shown), an observation
that is similar to that reported for newborn rat cardiac myocytes in
primary culture (21). In contrast, and as reported previously (18),
these cells were negative for myogenic differentiation markers, such as
myogenin, MyoD, and troponin T.
Ca2+ Channel Expression in RA-treated H9C2 Cells
Using RT-PCR, we have identified a change in Ca2+
channel
Modulation of L-type Calcium Channel Expression during Retinoic
Acid-induced Differentiation of H9C2 Cardiac Cells*
,
Muscles
et Pathologies, INSERM, St Eloi, 34000 Montpellier, France
![]()
ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
1S) and cardiac (
1C) L-type VDCCs during
cardiogenic differentiation in H9C2 cells that derived from embryonic
rat heart. We report that chronic treatment of H9C2 cells with 10 nM all-trans-retinoic acid
(all-trans-RA) enhanced cardiac Ca2+ channel
expression, as demonstrated by reverse transcription-polymerase chain
reaction, immunoblotting, and indirect immunofluorescence studies, as
well as patch-clamp experiments. In addition, RA treatment prevented
expression of functional skeletal L-type VDCCs, which were restricted
to myotubes that spontaneously appear in control H9C2 cultures
undergoing myogenic transdifferentiation. The use of specific skeletal
and cardiac markers indicated that RA, by preventing myogenic
transdifferentiation, preserves cardiac differentiation of this cell
line. Altogether, we provide evidence that cardiac and skeletal
subtype-specific L-type Ca2+ channels are relevant
functional markers of differentiated cardiac and skeletal myocytes,
respectively. In conclusion, our data demonstrate that in
vitro RA stimulates cardiac (
1C) L-type
Ca2+ channel expression, therefore supporting the
hypothesis that the RA pathway might be involved in the tissue specific
expression of Ca2+ channels in mature cardiac cells.
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
1C) channel subtype (1). However, despite the
large body of information on the properties of these VDCCs in adult
mammalian heart (1, 2), little is known concerning the regulation of
the functional expression of these channels in the developing heart. No
triggering or regulatory mechanism for cardiac L-type VDCC expression
has been clearly identified to date, although there is some evidence
that cardiac embryonic differentiation may be controlled by specific
inducers, such as transforming growth factor-
1 (3),
triiodothyronine (4), and retinoic acid (5).
1C versus
1S)
correlates well with specific differentiation processes, cardiogenesis
versus myogenesis.
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
20 °C. Aliquots were used only once and
diluted extemporaneously in 1% FCS culture medium in the dark.
1C and
1S was chosen
for its high sensitivity allowing adequate semiquantitation of these
transcripts. Total RNAs were prepared by using the guanidinium thiocyanate-phenol-chloroform procedure (14, 15) and stored in sterile
water. First strand cDNA synthesis was carried out for 1 h at
37 °C in 50 µl containing 5 µg of DNase treated-RNAs, 1 µl of
oligo(dT) primers (500 µg/ml), and Superscript II reverse transcriptase (50 units, Life Technologies, Inc.), according to the
manufacturer's instructions. The enzyme was then heat-inactivated (5 min at 95 °C).
1C and
1S were first assayed using full-length cDNAs of
these subunits (kindly supplied by Dr T. P. Snutch and B. Fontaine, respectively) as templates. Multiplex RT-PCR conditions
allowing the simultaneous amplification of a 377-base pair fragment
related to
1C (forward primer,
5'-GGAGAGTTTTCCAAAGAGAGG-3') and a 201-base pair fragment related to
1S (forward primer, 5'-CGCGAGGTCATGGACGTGGAG-3') were
optimized to allow maximal yield using a common reverse primer, 5'-GATCACCAGCCAGTAGAAGAC-3'. One-fifth (10 µl) of each PCR was electrophoretically separated on 2% agarose gels and stained with ethidium bromide. Gels were then scanned, and a densitometric analysis
was performed using ImageQuant (Molecular Dynamics). Gel figures were
produced using Adobe Photoshop (version 4.0) and printed on a Kodak
Colorease thermal sublimation printer. cDNA sequences were further
verified by sequencing.
1S subunit (mab427;
Chemicon) was used at a 1/100 dilution for indirect immunofluorescence experiments. A polyclonal antibody (pA1C) recognizing the
1C subunit was produced in rabbit (Eurogentec). It was
directed against a peptide from the intracellular II-III loop
(819-TKINMDDLQPSENEDKS-835) coupled to KLH. Working dilutions of the
crude serum for immunofluorescence experiments were in the range of
1/400 to 1/200. As a myogenic marker, we used a monoclonal antibody
specific of rat myogenin: the F5D hybridoma, kindly supplied by Dr.
Wright. The supernatant was used undiluted. In addition, a monoclonal
antibody specific of skeletal muscle troponin T (clone JLT-12; Sigma)
was used. In this case, the mouse IgG1 fraction was used at a 1/200
dilution in our immunofluorescence experiments. As a cardiac marker, we used a polyclonal antibody that specifically recognized myosin light
chain 2v (MLC-2v), kindly supplied by Drs. S. Kubalac and K. Chien.
Working dilutions for immunofluorescence experiments were in the range
of 1/100. A polyclonal antibody that specifically recognizes the
glyceraldehyde-3-phosphate dehydrogenase, kindly supplied by J. M. Blanchard (17), was used as internal control in Western blotting experiments.
-mercaptoethanol (5%) and bromphenol blue. Samples were then analyzed by SDS-polyacrylamide gel electrophoresis followed by Western
blot immunodetection. Briefly, after separation on SDS-polyacrylamide 7.5% gels, proteins were electrotransferred onto nitrocellulose membranes (40 mA, overnight). Membranes were immersed overnight at
4 °C in TBE buffer (90 mM Tris-borate, 2 mM
EDTA, pH 8) supplemented with 5% skim milk and 0.05% Tween. Membrane
strips were then incubated for 1 h at room temperature in primary
antibody solutions diluted in TBE containing 0.1% Tween and 5% skim
milk (mab427, 1/300; pA1C, 1/500) and rinsed three times for 10 min
each with TBE 0.05% Tween. Blots were subsequently incubated for 30 min at room temperature with horseradish peroxidase-conjugated
secondary antibody diluted at 1/5000 and washed three times before
visualizing the immunoreactive bands using ECL reagents (Amersham
Pharmacia Biotech), used according to the manufacturer's protocol. For
the detection of
1S in skeletal muscle extracts with
mab427, similar results were obtained using purified goat anti-mouse
IgG coupled to alkaline phosphatase (1/5000, Jackson ImmunoResearch
Laboratory). Membranes were then stripped in 100 mM
-mercaptoethanol, 2% SDS, 62.5 mM Tris-HCl, pH 6.8, at
50 °C for 30 min and reexposed to the glyceraldehyde-3-phosphate dehydrogenase antibody (17).
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-adrenergic agonist
isoproterenol (not shown), as described previously (11). A low voltage
activated Ba2+ current (T-type), observed in very few cells
(2 out of 80), was not characterized further.

View larger version (40K):
[in a new window]
Fig. 1.
Ba2+ current properties in
proliferating and differentiating H9C2 cells. Typical high voltage
activated Ba2+ currents recorded in freshly plated H9C2
cells cultured in 10% FCS (A) are presented in
B. Corresponding current density is presented as cardiac
(ICARD) and skeletal (ISKM) Ba2+
currents (C). Differentiating H9C2 cells cultivated in 1%
FCS for 5 days (D) present young myotubes, which exhibit a
mix of cardiac and skeletal Ba2+ currents (E and
F). Large myotubes found in cultures maintained in
differentiation conditions for up to 7 days (G) exhibit
typical ISKM Ba2+ currents (H and
I). A, D, and G are phase contrast
images of the corresponding cultures.

View larger version (81K):
[in a new window]
Fig. 2.
RA-induced differentiation of H9C2
cells. A phase-contrast image of typical cells treated with 10 nM all-trans-RA for 7 days is presented in
A, compared with control cells shown in B.
Hoescht 33258 labeling of the differentiated cells is shown in
RA-treated cultures (C) and control cultures (D).
The white outlines in C and D indicate
the approximate cell borders seen in longer exposures of the same field
and illustrate the nuclei arrangement of these cells. RA-differentiated
cells were not positive for the early myogenic marker, myogenin
(E), in contrast to myotubes present in control cultures
(F). Similarly, RA-exposed H9C2 cultures were negative for
troponin T (G), in contrast to control myotubes
(H). RA-treated cells were positive for MLC-2v
(I), in contrast to skeletal myotubes
(J). Arrowheads in E, G, and
J identify cells that exclude labeling for specific
markers.
1C and
1S subunit mRNA
distribution at a semiquantitative level. Multiplex PCR, performed with
a common antisense primer for the amplification of both
1C and
1S specific fragments (see under "Experimental Procedures"), was conducted by using
reverse-transcribed products from mRNAs collected at days 1, 2, 3, 5, and 10 in control (Fig. 3A)
and 10 nM all-trans-RA-treated (Fig.
3B) cultures. Similar results were obtained from three
independent batches of culture, thus indicating that the relative
changes in amounts of PCR fragments presented in Fig. 3 truly reflected
the effect of RA treatment. These experiments showed that the amount of
mRNA encoding
1S present in old control cultures
that contain large myotubes was increased (Fig. 3C). For
1C, we noticed that the amount of PCR products was
transiently enhanced at day 3 but declined in older cultures. By
contrast, the amount of
1C mRNA was increased in older cultures (Fig. 3D), whereas that of
1S
remained unchanged during cardiogenic differentiation of H9C2
cells.

View larger version (38K):
[in a new window]
Fig. 3.
RT-PCR detection of
1C and
1S transcripts. Photograph of
ethidium bromide gels corresponding to multiplex RT-PCR experiments
(see under "Experimental Procedures") for control (A)
and RA-treated (B) cultures performed at days 1 (D1), 2 (D2), 3 (D3), 5 (D5), and 10 (D10) after the application of 10 nM all-trans-RA, as indicated on the panels.
Right lane corresponds to molecular weight (mw).
Densitometric analysis of these gels is presented in C
(control) and D (RA-treated).
Immunoblotting Analysis of
1C and
1S
Proteins
At the protein level, the pore-forming subunits
1C
and
1S are the signature of the cardiac and skeletal
L-type channel expression, respectively. In our experiments, a
polyclonal antibody that recognized
1C (pA1C) and a
monoclonal antibody recognizing
1S (mab427) were used
(see under "Experimental Procedures"). mab427 (1/300) and pA1C
(1/500) antibodies reacted specifically with a 170-kDa protein (Fig.
4A) and a 195-kDa protein
(Fig. 4B), respectively, when used in Western blotting
experiments with skeletal muscle and heart membranes purified from a
2-month-old rat. The pA1C reactivity, which appeared as a single band,
could be blocked by preincubating the antibody with 3 µM
of free peptide (Fig. 4B), thus confirming the specificity
of pA1C for
1C.
|
Immunodetection of
1S and
1C proteins
with mab427 and pA1C was further performed using Western blots
generated with purified membrane protein preparations from control and
RA-treated H9C2 cells. These experiments were conducted several times,
and typical results are presented in Fig. 4, C and
D. In RA-treated cultures, mab427 revealed a faint band
(Fig. 4C), whereas the signal observed with pA1C was
stronger (Fig. 4D), compared with control cultures. Densitometric analysis revealed a 3-fold increase (3.1 ± 0.2) in
1C expression, whereas
1S exhibited a
2-fold decrease (2.1 ± 0.1) at the protein level. Similar results
were obtained with two other antibodies: (i) a polyclonal antibody that
recognizes
1C (kindly supplied by Dr. T.P. Snutch), and
(ii) a polyclonal antibody raised against purified skeletal muscle
Ca2+ channels that identifies
1S (Upstate
Biotechnology) (data not shown). Immunoblotting data thus demonstrated
that H9C2 cells expressed
1S and
1C
proteins typical of those present in rat skeletal and cardiac muscles
and that RA treatment of differentiating cells enhanced
1C expression while decreasing the amount of
1S protein.
Immunostaining of
1C and
1S Proteins
in Differentiating H9C2 Cells
Immunostaining patterns of
1S and
1C
proteins presented in Figs. 5 and
6 were obtained using the indirect
immunofluorescence technique performed with the mab427 and pA1C
antibodies from a representative batch of differentiated control and
RA-treated H9C2 cultures. Various controls including the immunostaining
of several cardiac and skeletal markers and nuclei visualization (with
Hoescht 33258) were concomitantly performed. The results described in
this section were reproduced in more than ten several independent
experiments.
|
|
In preliminary experiments performed with recombinant channel proteins
expressed in fibroblasts, we verified that both antibodies recognized
efficiently and specifically
1C and
1S
proteins (not shown). H9C2 myoblasts showed a positive staining with
pA1C (1/200) (Fig. 5A), in good agreement with
electrophysiological data described above. The specific staining
observed with pA1C was blocked upon incubation with 3 µM
of the corresponding
1C peptide (Fig. 5B). By
contrast, the monoclonal antibody mab 427 (1/100) generated only a
background of labeling in H9C2 myoblasts, indicating that there was no
expression, or very little, of the
1S isoform at the
myoblast stage (Fig. 5C). A positive staining could be
observed with mab427 in two-nuclei myotubes (Fig. 5C,
arrowhead), indicating that
1S was expressed
concomitantly to myoblast fusion.
Immunofluorescence studies were then performed on differentiated
control and RA-treated cells (10 nM
all-trans-RA). Large myotubes found in control cultures
maintained for up to 7 days in differentiating medium (1% FCS) were
markedly stained with mab427 (Fig. 5D), similarly to that
described for cultured myotubes stained with antibody (16, 22). These
myotubes exhibited a typical punctuate pattern with membrane "hot
spot" for
1S immunostaining. Hot spot staining for
1S could be preferentially observed at the edge of the
membrane area of the myotubes as well as in the close vicinity of the
nuclei (Fig. 5D, arrowheads). In most RA-treated cells,
1S immunostaining was close to the background level in most cells, although a small percentage of these cells (<10%) did
show a positive mab427 labeling (Fig. 5E). This staining was weak in intensity and different from the typical
1S
immunostaining described for myotubes because it was rather homogeneous
throughout the membrane surface in these cells. Although this
observation is in good agreement with the immunoblotting data, it is
nevertheless intriguing from a functional point of view, because none
of the cells present in RA-treated cultures that we examined by
electrophysiology exhibited a slow Ba2+ current similar to
ISKM found in control myotubes (see below).
In RA-treated cultures, we observed a stronger staining with the pA1C
antibody, compared with control H9C2 cells (Fig. 5, F and
G). H9C2 cells in control cultures, even large myotubes, displayed a weak pA1C staining (Fig. 5F). However, we have
evidence that the labeling of large myotubes is less specific than that in mononucleated cells because preimmune serum showed similar labeling
of these cells (not shown). When H9C2 cells were cultivated in the
presence of RA during differentiation, pA1C staining was enhanced,
revealing a marked increase in
1C protein expression that was observed both in mononucleated and multinucleated cells (Fig.
5G). Clearly, the pattern of
1C staining in
RA-treated cells was different from the pattern of
1S
staining in myotubes. Staining for
1C is more diffuse
and can be observed all over the membrane surface with some circular
spots of higher intensity (Fig. 5G,
arrowheads).
To further characterize the
1C and
1S
stainings, we performed double labeling experiments with the pA1C and
mab427 antibodies in differentiated H9C2 cells. Results presented in
Fig. 6 show that
1C and
1S expressions
are mutually exclusive in differentiated cells, under both untreated
and RA-treated culture conditions. In a control myotube exhibiting
typical hot spot and punctate pattern for
1S staining,
only a background of pA1C labeling could be observed (Fig. 6,
A-C). In contrast, in cells present in cultures treated
with 10 nM all-trans-RA, a weak
1S staining was observed (Fig. 6D), whereas
pA1C labeling revealed an intense staining with a typical spot of
1C staining (Fig. 6E).
Functional Expression of L-type Ca2+ Channels in RA-treated H9C2
Cardiac-type Ba2+ currents (ICARD) were
recorded both in multinucleated and mononucleated cells present in
differentiating H9C2 cultures treated with RA analogs (Fig.
7). In multinucleated cells, ICARD exhibited typical properties of a cardiac L-type
current (Fig. 7A). Interestingly, the inactivation kinetics
was faster for Ba2+ currents recorded on multinucleated
cells (
fast = 47 ± 12 ms at 10 mV;
n = 6) than with mononucleated cells (Fig.
7B). In both multinucleated and in mononucleated cells,
ICARD was modulated by dihydropyridine molecules, as
illustrated by the block observed following application of 1 µM PN 200-110 (Fig. 7, A and B, open symbols). These two types of cells exhibited ICARD
with similar current-voltage relationships, as illustrated in Fig.
7C. No ISKM was detected in multinucleated cells
(n > 40) in RA-treated cultures (Fig. 7, A and
D), unlike multinucleated cells (myotubes) in control cultures or cultures treated with Me2SO (1%) or 8Br-cAMP
(1 µM) that showed comparable density for
ISKM (Fig. 7D). Furthermore, we report here that
the cardiac current density was significantly higher in multinucleated
cells (5.9 ± 1.8 pA/pF; n = 25) than in
mononucleated cells from RA-treated cultures (1.4 ± 0.9 pA/pF; n = 8) or in myoblasts (2.5 ± 0.9 pA/pF;
n = 7) and differentiating myotubes cultivated in
control conditions (Fig. 7D). Comparable results were
obtained using 100 nM 9-cis-RA instead of 10 nM all-trans-RA (Fig. 7D). Direct
modulation of cardiac or skeletal L-type Ca2+ channels by
RA could be ruled out in our experiments because no change in L-type
current properties were observed in cells acutely treated with 0.1 µM RA.
|
| |
DISCUSSION |
|---|
|
|
|---|
The important finding of this study is that expression of cardiac
(
1C) L-type voltage-dependent
Ca2+ channels is up-regulated during retinoic acid-induced
differentiation of embryonic cardiac H9C2 cells. The data also provide
strong evidence that myogenic transdifferentiation of H9C2 cells is
suppressed by RA treatment, further supporting the possibility that RA
favors establishment of the cardiac phenotype in H9C2 cells.
Altogether, our analysis of Ca2+ channel activity in
differentiating H9C2 cells supports the hypothesis that
1C and
1S channel proteins are phenotypic
markers of cardiogenic and myogenic differentiation, respectively.
Despite their cardiac origin, defined by the expression of cardiac markers such as MLC-2a and MLC-2v at the myoblast stage (20), differentiating H9C2 cells cultivated in a low concentration of serum transdifferentiate and acquire a skeletal muscle phenotype. Evidence for skeletal muscle differentiation of H9C2 cells is based on several criteria, including myoblast fusion; expression of specific markers, such as myogenin, troponin T, and MyoD; and nicotinic receptors (10). Expression of myogenin and MyoD, two specific markers of skeletal muscle differentiation, has not been described in cardiac cells (23). In contrast, skeletal muscle differentiation can be induced in cardiac cells when myogenic factors are overexpressed (24). Myogenic differentiation of H9C2 cells is not caused by a constitutive expression of myogenic factors but most likely results from a transdifferentiation process responsible for a phenotypic switch from cardiac to skeletal muscle.
Chronic treatment with RA can prevent transdifferentiation of H9C2 cells because no typical myotubes could be observed in these cultures. We describe the presence of multinucleated cells in RA-treated cultures, but we have no evidence to date that myoblast fusion occurs in RA-treated H9C2 cultures, and we suggest that an alternative mechanism is involved. It has been shown that DNA replication followed by karyokinesis without cell division occurs in cardiac myocytes giving rise to adult binucleated cells, and cardiomyocytes can become multinucleated when cultured (25). The latter mechanism, although not yet proven, seems likely to operate in RA-treated H9C2 cultures. RA has been shown to affect myogenic differentiation in different ways; it inhibits myogenic differentiation of embryonic muscle cells in primary cultures (26) while enhancing myogenin and MyoD expression and myoblast fusion in skeletal muscle cell lines (C2 and L6) (27). H9C2 cells exposed to RA are negative for skeletal markers, indicating, therefore, that RA inhibits myogenic differentiation of these cells.
Our data show that chronic treatment of H9C2 cells with RA analogs
maintains their cardiac phenotype. The expression of MLC-2v even
suggests that RA-treated cells exhibit enhanced cardiac differentiation that occurs with a ventricular specification (20, 28). Recently, the
role of RA in heart development has been assessed in genetically manipulated mouse lines (29, 30). Targeted disruption of the gene
encoding RXR
subunits resulted in mice showing ventricular chamber
defects reminiscent of vitamin A deficiency syndrome (31-33). However,
it remains unclear whether a direct RA-dependent pathway is
necessary for proper heart development (34). In contrast, in
vitro studies have indicated essential involvement of the
RA-dependent pathways in the establishment and maintenance
of cardiac differentiation in stem cell-derived cardiomyocytes and
neonatal rat cardiac myocytes (20, 35, 36). Consistent with these
observations, treatment of P19 embryonic carcinoma cells with RA
favored cardiac commitment (37). In a similar manner, the requirement
for RA in the maintenance of the cardiac phenotype of several cell
lines such as QCE-6 (38) and HL-1 (39) has been shown. Because H9C2
cells are easy to manipulate, more and more investigations are
performed with this cell line. We have shown that H9C2 cell line is a
suitable cardiac cellular model when exposed to RA, and therefore, our
study is an important contribution that delineates the experimental
requirements for the maintenance of the cardiac phenotype of this cell
line. Consequently, we suggest that H9C2 cells can serve as a model system for a variety of investigations that are difficult to handle on
primary cardiac myocytes or related to cardiac maturation.
An up-regulation of cardiac/
1C L-type Ca2+
channel expression is observed in association with RA treatment. The
increase in
1C expression is most likely a consequence
of the sustained cardiac phenotype because it correlates with MLC-2v
expression. Similarly, increased expression of functional cardiac
L-type Ca2+ channels was observed in developing
cardiomyocytes derived from embryoid bodies (9), further indicating
that this channel is an hallmark of early cardiogenesis. We have
demonstrated that an important consequence of both myogenic and
cardiogenic differentiation is the triggering and tuning of the
expression of functional L-type channel isotypes. Untreated H9C2
myoblasts or RA-treated cells exhibit typical cardiac L-type
Ca2+ channels. In contrast, H9C2 cells that have undergone
transdifferentiation to a myogenic phenotype express skeletal muscle
L-type Ca2+ channels. Overall, our data reconcile some of
the apparent discrepancies between previous studies, which reported the
simultaneous presence of cardiac and skeletal isoforms of the L-type
Ca2+ channel in this cell line (11, 12). Both biochemical
and patch-clamp experiments were necessary to delineate the expression patterns of these channel isotypes during differentiation. Altogether, our data lead us to conclude that the electrophysiological properties of these two channel isotypes in H9C2 cells are similar to those found
in previous studies (2, 40). H9C2 cells can therefore be exploited for
further channel investigations, such as subunit modulation,
pharmacology, and regulation pathways, known to modulate cardiac or
skeletal Ca2+ channels. In addition, it will be important
to determine whether Ca2+ channel expression, using
antisense or overexpression strategies, influences the differentiation
pathways of H9C2 cells.
The identification of a cardiac-to-skeletal transdifferentiation
process in vitro provides an opportunity to study the
specificity of cardiac and skeletal muscle differentiation programs.
Cardiac development proceeds from the initial commitment of
mesodermally derived progenitors, as for skeletal muscle. The
transition of embryonic to adult cardiomyocytes is accompanied by
changes in the expression patterns of a variety of contractile protein
isoforms. Several fetal isoforms, including skeletal muscle
-actin
(41), are identified as skeletal muscle isoforms. Whether cardiomyocyte maturation is accompanied by changes in Ca2+ channel
subunit or isotype expression has not been studied. Whether developing
cardiomyocytes that derive from embryoid bodies (9) have the potential
to undergo a myogenic transdifferentiation and/or express several
isotypes of Ca2+ channels is also unknown and remains
important to evaluate. In this respect, it is important to note that
newborn cardiac myocytes in primary culture express functional
1S that generates contractile activity (42). Conversely,
skeletal muscle cells in vitro, as well as developing muscle
cells in vivo, do express cardiac
1C mRNA
(43, 44). Altogether, our data provide new insights into the
tissue-specific expression of L-type Ca2+ channel isotypes
and further suggest that the expression of functional skeletal L-type
Ca2+ channels can occur within the cardiac cell lineage
through a de-differentiation process demonstrated in vitro
in a cardiac cell line model. It is now important to search for the
Ca2+ channel isotypes, including
1S, that
are expressed in early stages of cardiac development. Our study should
also fosters in vivo investigations, such as in animal
models that have been genetically manipulated for their RXR
pathway
(31, 34), to probe whether Ca2+ channel expression is altered.
De-differentiation that occurs during cardiac pathologies might favor
de novo expression of channel proteins, such as T-type Ca2+ channels (45) and pacemaker channels (46). Preliminary
experiments also indicate the presence of a skeletal L-type
Ca2+ channel in cardiomyocytes obtained from diseased human
hearts, because expression of the
1S subunit can be
identified at both transcript and protein levels (47). These results
raise the question of whether expression of skeletal L-type
Ca2+ channels in heart is functionally relevant. Such a
channel activity has not been described to date in hypertrophy models
(48). However, functional expression of
1S-related
Ca2+ channels that act mainly as a voltage sensor is
expected to be difficult to identify in cardiac myocytes, and combined
patch-clamp, contraction, and Ca2+ imaging experiments will
certainly be necessary to resolve this issue. In addition, it will be
now important to determine whether the RA treatment can improve
alterations of Ca2+ handling properties identified in
cardiac pathologies, such as hypertrophy and congestive heart failure.
| |
ACKNOWLEDGEMENTS |
|---|
We are grateful to Drs. K. Chien and S. Kubalac (University of California at San Diego, La Jolla, CA) for providing us MLC-2a and MLC-2v polyclonal antibodies and stimulating discussions. We gratefully acknowledge Dr. E. Wright (University of Texas, Dallas, TX) for providing us anti-rat myogenin monoclonal antibody (F5D hybridoma), Dr. J. M. Blanchard (Institut de Genetique Moléculaire, Montpellier, France) for glyceraldehyde-3-phosphate dehydrogenase antibody, and Dr. M. Vandromme for expertise and discussions regarding stainings for skeletal muscle markers. We also thank Dr. J. B. Lazaro for his help with BrdUrd labelings and Drs. A. Fernandez, N. J. Lamb, G. Carnac S. Richard, A. Le Cam, and D. Fisher for stimulating discussions and critical reading of the manuscript.
| |
FOOTNOTES |
|---|
* This work was supported in part by the Association Française contre les Myopathies, Association pour la Recherche contre le Cancer Grant ARC9011, Ministère de la Recherche Grant ACC-9, Sciences du Vivant, and the Program Génome du CNRS. A travel grant was provided by the Center Européen de Bioprospectives and Dr. B. Pourrias.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
§ To whom correspondence should be addressed. Tel.: 33-499-61-99-36; Fax: 33-499-61-99-01; E-mail: philippe.lory@igh.cnrs.fr.
| |
ABBREVIATIONS |
|---|
The abbreviations used are: VDCC, voltage-dependent calcium channel; RA, retinoic acid; PBS, phosphate-buffered saline; FCS, fetal calf serum; RT, reverse transcription; PCR, polymerase chain reaction; MLC, myosin light chain.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Hofmann, F., Biel, M., and Flockerzi, V. (1994) Annu. Rev. Neurosci. 17, 399-418[CrossRef][Medline] [Order article via Infotrieve] |
| 2. |
McDonald, T. F.,
Pelzer, S.,
Trautwein, W.,
and Pelzer, D. J.
(1994)
Physiol. Rev.
74,
365-507 |
| 3. |
Eghbali, M.,
Tomek, R.,
Woods, C.,
and Bhambi, B.
(1991)
Proc. Natl. Acad. Sci. U. S. A.
88,
795-799 |
| 4. | Rodriguez, E. R., Tan, C. D., Onwuta, U. S., Yu, Z. X., Ferrans, V. J., and Parrillo, J. E. (1994) Biochem. Biophys. Res. Commun. 205, 652-658[CrossRef][Medline] [Order article via Infotrieve] |
| 5. | Kastner, P., Grondona, J. M., Mark, M., Gansmuller, A., LeMeur, M., Decimo, D., Vonesch, J. L., Dolle, P., and Chambon, P. (1994) Cell 78, 987-1003[CrossRef][Medline] [Order article via Infotrieve] |
| 6. | Olson, E. N. (1992) Dev. Biol. 154, 261-272[CrossRef][Medline] [Order article via Infotrieve] |
| 7. | Cognard, C., Constantin, B., Rivet-Bastide, M., Imbert, N., Besse, C., and Raymond, G. (1993) Development 117, 1153-1161[Abstract] |
| 8. |
Maltsev, V. A.,
Wobus, A. M.,
Rohwedel, J.,
Bader, M.,
and Hescheler, J.
(1994)
Circ. Res.
75,
233-244 |
| 9. |
Kolossov, E.,
Fleischmann, B. K.,
Liu, Q.,
Bloch, W.,
Viatchenko-Karpinski, S.,
Manzke, O.,
Ji, G. J.,
Bohlen, H.,
Addicks, K.,
and Hescheler, J.
(1998)
J. Cell Biol.
143,
2045-2056 |
| 10. | Kimes, B. W., and Brandt, B. L. (1976) Exp. Cell Res. 98, 367-381[CrossRef][Medline] [Order article via Infotrieve] |
| 11. |
Hescheler, J.,
Meyer, R.,
Plant, S.,
Krautwurst, D.,
Rosenthal, W.,
and Schultz, G.
(1991)
Circ. Res.
69,
1476-1486 |
| 12. | Mejia-Alvarez, R., Tomaselli, G. F., and Marban, E. (1994) J. Physiol. 478, 315-329[Medline] [Order article via Infotrieve] |
| 13. | Lory, P., Varadi, G., Slish, D. F., Varadi, M., and Schwartz, A. (1993) FEBS Lett. 315, 167-172[CrossRef][Medline] [Order article via Infotrieve] |
| 14. | Chomczynski, P., and Sacchi, N. (1987) Anal. Biochem. 162, 156-159[Medline] [Order article via Infotrieve] |
| 15. |
Lory, P.,
Rassendren, F. A.,
Richard, S.,
Tiaho, F.,
and Nargeot, J.
(1990)
J. Physiol.
429,
95-112 |
| 16. | Morton, M. E., and Froehner, S. C. (1989) Neuron 2, 1499-1506[CrossRef][Medline] [Order article via Infotrieve] |
| 17. | Philips, A., Huet, X., Plet, A., Rech, J., Vie, A., and Blanchard, J. M. (1999) Oncogene 18, 1819-1825[CrossRef][Medline] [Order article via Infotrieve] |
| 18. | Lory, P., Pupier, S., Goudet, C., and Nargeot, J. (1995) Biophys. J. 68, A259 |
| 19. |
Beam, K. G.,
and Knudson, C. M.
(1988)
J. Gen. Physiol.
91,
781-798 |
| 20. |
Kubalak, S. W.,
Miller-Hance, W. C.,
O'Brien, T. X.,
Dyson, E.,
and Chien, K. R.
(1994)
J. Biol. Chem.
269,
16961-16970 |
| 21. |
Zhou, M. D.,
Sucov, H. M.,
Evans, R. M.,
and Chien, K. R.
(1995)
Proc. Natl. Acad. Sci. U. S. A.
92,
7391-7395 |
| 22. |
Powell, J. A.,
Petherbridge, L.,
and Flucher, B. E.
(1996)
J. Cell Biol.
134,
375-387 |
| 23. | Edmondson, D. G., Lyons, G. E., Martin, J. F., and Olson, E. N. (1994) Development 120, 1251-1263[Abstract] |
| 24. | Miner, J. H., Miller, J. B., and Wold, B. J. (1992) Development 114, 853-860[Abstract] |
| 25. | Claycomb, W. C., and Bradshaw, H. D. (1983) Dev. Biol. 99, 331-337[CrossRef][Medline] [Order article via Infotrieve] |
| 26. |
Xiao, Y.,
Grieshammer, U.,
and Rosenthal, N.
(1995)
J. Cell Biol.
129,
1345-1354 |
| 27. | Albagli-Curiel, O., Carnac, G., Vandromme, M., Vincent, S., Crepieux, P., and Bonnieu, A. (1993) Differentiation 52, 201-210[CrossRef][Medline] [Order article via Infotrieve] |
| 28. |
Chien, K. R.
(1993)
Science
260,
916-917 |
| 29. | Sucov, H. M., and Evans, R. M. (1995) Mol. Neurobiol. 10, 169-184[Medline] [Order article via Infotrieve] |
| 30. | Chambon, P. (1996) FASEB J. 10, 940-954[Abstract] |
| 31. |
Dyson, E.,
Sucov, H. M.,
Kubalak, S. W.,
Schmid-Schonbein, G. W.,
DeLano, F. A.,
Evans, R. M.,
Ross, J., Jr.,
and Chien, K. R.
(1995)
Proc. Natl. Acad. Sci. U. S. A.
92,
7386-7390 |
| 32. | Gruber, P. J., Kubalak, S. W., Pexieder, T., Sucov, H. M., Evans, R. M., and Chien, K. R. (1996) J. Clin. Invest. 98, 1332-1343[Medline] [Order article via Infotrieve] |
| 33. | Sucov, H. M., Lou, J., Gruber, P. J., Kubalak, S. W., Dyson, E., Gumeringer, C. L., Lee, R. Y., Moles, S. A., Chien, K. R., Giguere, V., and Evans, R. M. (1996) Biochem. Soc. Symp. 62, 143-156[Medline] [Order article via Infotrieve] |
| 34. | Chen, J., Kubalak, S. W., and Chien, K. R. (1998) Development 125, 1943-1949[Abstract] |
| 35. |
Wu, J.,
Garami, M.,
Cao, L.,
Li, Q.,
and Gardner, D. G.
(1995)
Am. J. Physiol.
268,
E1108-E1113 |
| 36. | Wobus, A. M., Kaomei, G., Shan, J., Wellner, M. C., Rohwedel, J., Ji, G., Fleischmann, B., Katus, H. A., Hescheler, J., and Franz, W. M. (1997) J. Mol. Cell. Cardiol. 29, 1525-1539[CrossRef][Medline] [Order article via Infotrieve] |
| 37. | Rudnicki, M. A., Reuhl, K. R., and McBurney, M. W. (1989) Development 107, 361-372[Abstract] |
| 38. |
Eisenberg, C. A.,
and Bader, D. M.
(1996)
Circ. Res.
78,
205-216 |
| 39. |
Claycomb, W. C.,
Lanson, N. A., Jr.,
Stallworth, B. S.,
Egeland, D. B.,
Delcarpio, J. B.,
Bahinski, A.,
and Izzo, N. J., Jr.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
2979-2984 |
| 40. | Catterall, W. A. (1995) Annu. Rev. Biochem. 64, 493-531[CrossRef][Medline] [Order article via Infotrieve] |
| 41. |
Swynghedauw, B.
(1986)
Physiol. Rev.
66,
710-771 |
| 42. | Haase, H., Wallukat, G., Flockerzi, V., Nastainczyk, W., and Hofmann, F. (1994) Recept. Chann. 2, 41-52[Medline] [Order article via Infotrieve] |
| 43. | Chaudhari, N., and Beam, K. G. (1993) Dev. Biol. 155, 507-515[CrossRef][Medline] [Order article via Infotrieve] |
| 44. | Bulteau, L., Raymond, G., and Cognard, C. (1998) J. Cell Sci. 111, 2149-2158[Abstract] |
| 45. |
Nuss, H. B.,
and Houser, S. R.
(1993)
Circ. Res.
73,
777-782 |
| 46. |
Cerbai, E.,
Pino, R.,
Porciatti, F.,
Sani, G.,
Toscano, M.,
Maccherini, M.,
Giunti, G.,
and Mugelli, A.
(1997)
Circulation
95,
568-571 |
| 47. | Ménard, C., Lory, P., Richard, S., and Nargeot, J. (1998) J. Mol. Cell. Cardiol. 30, A126 |
| 48. |
Gaughan, J. P.,
Hefner, C. A.,
and Houser, S. R.
(1998)
Am. J. Physiol.
275,
H577-H590 |